<p>Teriflunomide Viatris is a medicine used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation attacks the protective covering (sheath) around nerves and damages the nerves themselves.</p><p>Teriflunomide Viatris is used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).</p><p>Teriflunomide Viatris contains the active substance teriflunomide and is a ‘generic medicine’. This means that Teriflunomide Viatris contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Aubagio. For more information on generic medicines, see the question-and-answer document <a href="https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf">here</a>.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Teriflunomide Mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 of the SmPC for important information on the population for which efficacy has been established).</p> <p><span lang="EN-GB"> </span></p> </div>
Therapeutic Area (MeSH)
ATC Code
L04AK02
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| teriflunomide | N/A | teriflunomide |
EMA Name
Teriflunomide Viatris (previously Teriflunomide Mylan)
Medicine Name
Teriflunomide Viatris (previously Teriflunomide Mylan)
Aliases
N/ANo risk management plan link.